Form 4 for BLFS BIOLIFE SOLUTIONS INC

Accepted 2023-01-10 00:00:00 ET · period of report 2023-01-03 · accession 0001437749-23-000818 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-01-10	2023-01-03	BLFS	Schulz Marcus	Chief Revenue Off	A - Grant	—	+12.7K	48.2K	+36%	—
D	2023-01-10	2023-01-03	BLFS	Schulz Marcus	Chief Revenue Off	A - Grant	$0.00	+12.7K	12.7K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-01-03	A	A	12,733	—	48,233	D	—	—	(F1) The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.
2	Derivative	Restricted Stock Award	2023-01-03	A	A	12,733	$0.00	12,733	D	$0.00 · — to —	12,733 Common Stock	(F2) The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.